Genitourinary Cancer

The National Comprehensive Cancer Network (NCCN) has added apalutamide (Erleada) to its category 1 recommendations for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The FDA has approved a supplemental biologics license application to add a 4-week dosing schedule for nivolumab (Opdivo) across several of the PD-1 inhibitor’s indications.

Patients with nonmetastatic castration-resistant prostate cancer now have their first FDA-approved treatment. Apalutamide (Erleada) was approved based on the phase III SPARTAN trial in which apalutamide reduced the risk of metastasis or death by 72% in patients with nonmetastatic CRPC.

William C. Huang, MD, discusses the transition from open cystectomy to minimally invasive robotic-assisted surgery in the management of muscle-invasive bladder cancer.

Based on findings from the phase III LATITUDE trial, the Food and Drug Adminstration has approved abiraterone acetate (Zytiga) for use in high-risk patients with castration-sensitive prostate cancer.

The year 2017 saw significant advancements in the field of bladder cancer treatment. Five Food and Drug Administration (FDA) approvals for checkpoint inhibitors in both the first and second line setting opened up the immunotherapy landscape, and more develoments are on the way.

Cisplatin, a platinum-based chemotherapy agent that is used to treat testicular cancer, non-small cell lung cancer, bladder cancer, cervical cancer, ovarian cancer and head and neck cancer, has been found to cause a significant amount of hearing loss in patients, according to a recent article published in Nature Communications.

The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab (Keytruda), a PD-1 inhibitor, and lenvatinib (Lenvima), a VEGF/FGF inhibitor, for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC).

The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Apalutamide is an oral androgen receptor inhibitor.

The FDA approved abozantinib (Cabometyx) for use in previously untreated patients who have advanced renal cell carcinoma (RCC).

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for use of this combination as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).

Adjuvant therapy is associated with high toxicity and most patients will derive no benefit, Umberto Capitanio, MD, San Raffaele Scientific Institute, Milan, Italy, said in a presentation during the 2017 EMUC Congress. However, adjuvant therapy “might show the highest ratio between clinical benefit and toxicity” in this specific subset of high-risk patients.

“Are there ways that we can optimize the cure rates with HIFU? When are people recurring? What are we missing when they recur? What are the true rates of complications? We do not know the answer to most of these questions,” says Jonathan Warner, MD.

Maria De Santis, MD, associate clinical professor at the University of Warwick, discussed the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.

Radical prostatectomy was not associated with significantly lower all-cause or prostate-cancer mortality than observation.

FDA approval was given to a new regimen of cabazitaxel (Jevtana) to treat men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The approval is for 20 mg/m2 every 3 weeks in combination with prednisone. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010.

Patients with untreated advanced renal cell carcinoma (RCC) lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent), according to results of an independent review of the randomized CABOSUN trial reported at the 2017 ESMO Congress in Madrid.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

Updated United States Preventive Services Task Force (USPSTF) guidelines on prostate cancer screening were recently published in Cancer.

A patient can experience less pain, a quicker healing time and potentially more normal kidney function, due to the minimally invasive aspect of robotic surgery, according to Ketan K. Badani, M.D.

Bladder cancer is uncommon, and is more often diagnosed at an advanced stage because it has symptoms that mimic other disorders.

For years, people believed that there was a link between vasectomies and prostate cancer.

The risk of developing certain types of cancer can be increased by exposure to work-related stress.

Researchers found that the rate of suicide in patients with lung cancer is much higher than those with other types of cancer.